Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

British Journal of Cancer

Volumn 104, Issue 9, 2011, Pages 1418-1425

  Bignotti, E ^a   Ragnoli, M ^a   Zanotti, L ^a   Calza, S ^a   Falchetti, M ^a   Lonardi, S ^a   Bergamelli, S ^a   Bandiera, E ^a   Tassi, R A ^a   Romani, C ^a   Todeschini, P ^a   Odicino, F E ^a   Facchetti, F ^a   Pecorelli, S ^a   Ravaggi, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

diagnosis; endometrial carcinoma; HE4; prognosis; serum marker

Indexed keywords

PROTEIN; PROTEIN HE4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADULT; AGED; ANALYSIS OF VARIANCE; CA-125 ANTIGEN; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79955473616     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.109     Document Type: Article

References (28)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366(9484): 491-505 (Pubitemid 41111699)
2. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG (2010) HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 31(2): 113-119
3. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD (2006) Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 103(2): 405-416 (Pubitemid 44602159)
4. Bingle L, Singleton V, Bingle CD (2002) The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21(17): 2768-2773 (Pubitemid 34478335)
5. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17 (Pubitemid 13194678)
6. Cirisano Jr FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL (1999) Epidemiologic and surgicopatho-logic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74(3): 385-394 (Pubitemid 29439878)
7. Cirisano Jr FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL (2000) The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77(1): 55-65 (Pubitemid 30217305)
8. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the corpus uteri. J Epidemiol Biostat 6(1): 47-86
9. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3): 837-845
10. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6): 2162-2169 (Pubitemid 40490123)
11. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW (1986) CA125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155(5): 1097-1102 (Pubitemid 17176689)
12. Galgano MT, Hampton GM, Frierson Jr HF (2006) Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19(6): 847-853 (Pubitemid 43780455)
13. Gemer O, Uriev L, Harkovsky T, Peled R, Ben-Dor D, Barak F, Segal S (2004) The significance of the degree of myometrial invasion in patients with stage IB endometrial cancer. Eur J Gynaecol Oncol 25(3): 336-338 (Pubitemid 38585618)
14. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103(1): 155-159 (Pubitemid 44374683)
15. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 110(3): 374-382
16. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A (2009) Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 100(8): 1315-1319
17. Kirchhoff C, Habben I, Ivell R, Krull N (1991) A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 45(2): 350-357
18. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A (1996) p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 175(5): 1246-1252 (Pubitemid 26398986)
19. Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A (2001) Favorable survival associated with microsatellite instability in endome-trioid endometrial cancers. Obstet Gynecol 97(3): 417-422 (Pubitemid 32184704)
20. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S, Franchi M, Guidi GC (2009) The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23(5): 331-335
21. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast Jr RC, Lu K (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110(2): 196-201
22. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24(15): 2376-2385 (Pubitemid 46630670)
23. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH (2005) Preoperative serum CA125 levels in treating endometrial cancer. J Reprod Med 50: 585-590 (Pubitemid 41193137)
24. R Development Core Team (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org
25. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA, Gynecologic Oncology Group Study (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24(1): 36-44 (Pubitemid 46630491)
26. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A (1998) PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4(12): 3005-3010 (Pubitemid 29001474)
27. Sherman ME (2000) Theories of endometrial carcinogenesis: a multi-disciplinary approach. Mod Pathol 13(3): 295-308 (Pubitemid 30207514)
28. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M (1997) Value of preoperative CA125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 90: 441-447 (Pubitemid 27357939)